DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,034 filers reported holding DANAHER CORPORATION in Q1 2023. The put-call ratio across all filers is 0.99 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24,257,729 | +6.0% | 97,774 | +2.6% | 0.83% | +9.2% |
Q2 2023 | $22,875,600 | +1.3% | 95,315 | +6.4% | 0.76% | -5.8% |
Q1 2023 | $22,584,548 | -10.5% | 89,607 | -5.7% | 0.81% | -10.9% |
Q4 2022 | $25,226,313 | +6.6% | 95,043 | +3.8% | 0.91% | -0.1% |
Q3 2022 | $23,656,000 | -5.9% | 91,586 | -7.7% | 0.91% | +0.3% |
Q2 2022 | $25,151,000 | -16.5% | 99,208 | -3.4% | 0.90% | 0.0% |
Q1 2022 | $30,133,000 | -10.5% | 102,726 | +0.3% | 0.90% | -5.3% |
Q4 2021 | $33,682,000 | +5.3% | 102,373 | -2.6% | 0.96% | -2.3% |
Q3 2021 | $31,983,000 | +11.5% | 105,056 | -1.7% | 0.98% | +14.0% |
Q2 2021 | $28,679,000 | +18.7% | 106,869 | -0.4% | 0.86% | +13.2% |
Q1 2021 | $24,154,000 | -2.4% | 107,314 | -3.7% | 0.76% | -7.8% |
Q4 2020 | $24,748,000 | +1.4% | 111,405 | -1.7% | 0.82% | -8.4% |
Q3 2020 | $24,396,000 | +10.2% | 113,295 | -9.5% | 0.90% | +3.0% |
Q2 2020 | $22,146,000 | +28.0% | 125,237 | +0.2% | 0.87% | +4.7% |
Q1 2020 | $17,305,000 | -8.7% | 125,026 | +1.2% | 0.83% | +23.5% |
Q4 2019 | $18,954,000 | +15.1% | 123,492 | +8.3% | 0.67% | +7.7% |
Q3 2019 | $16,465,000 | +0.5% | 113,997 | -0.5% | 0.62% | +0.8% |
Q2 2019 | $16,380,000 | +7.3% | 114,607 | -0.9% | 0.62% | +4.9% |
Q1 2019 | $15,270,000 | +17.2% | 115,662 | -8.5% | 0.59% | +3.5% |
Q4 2018 | $13,033,000 | -5.0% | 126,387 | +0.1% | 0.57% | +17.7% |
Q3 2018 | $13,719,000 | +9.9% | 126,252 | -0.2% | 0.48% | +3.9% |
Q2 2018 | $12,486,000 | +0.5% | 126,535 | -0.2% | 0.47% | -0.2% |
Q1 2018 | $12,418,000 | +5.1% | 126,835 | -0.3% | 0.47% | +15.0% |
Q4 2017 | $11,814,000 | +8.7% | 127,275 | +0.5% | 0.41% | +8.0% |
Q3 2017 | $10,864,000 | -9.1% | 126,650 | -10.6% | 0.38% | -8.5% |
Q2 2017 | $11,958,000 | -0.3% | 141,700 | +1.1% | 0.41% | -2.6% |
Q1 2017 | $11,991,000 | +126.7% | 140,201 | +106.3% | 0.42% | +121.5% |
Q4 2016 | $5,290,000 | +17.0% | 67,956 | +17.8% | 0.19% | +16.5% |
Q3 2016 | $4,522,000 | -3.8% | 57,691 | +24.0% | 0.16% | -4.1% |
Q2 2016 | $4,701,000 | +7.3% | 46,541 | +0.8% | 0.17% | +8.9% |
Q1 2016 | $4,381,000 | +6.5% | 46,180 | +4.3% | 0.16% | +18.0% |
Q4 2015 | $4,112,000 | +40.5% | 44,270 | +28.9% | 0.13% | +40.0% |
Q3 2015 | $2,927,000 | +30.4% | 34,355 | +31.0% | 0.10% | +48.4% |
Q2 2015 | $2,245,000 | +1.7% | 26,230 | +0.9% | 0.06% | 0.0% |
Q1 2015 | $2,207,000 | -6.9% | 26,000 | -6.0% | 0.06% | -9.9% |
Q4 2014 | $2,370,000 | +11.9% | 27,650 | -0.8% | 0.07% | +7.6% |
Q3 2014 | $2,118,000 | -88.5% | 27,875 | -88.0% | 0.07% | -88.3% |
Q2 2014 | $18,339,000 | +3467.9% | 232,935 | +3300.5% | 0.56% | +3205.9% |
Q1 2014 | $514,000 | – | 6,850 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |